Gilteritinib in combination with venetoclax, low-dose cytarabine and actinomycin D for relapsed or refractory FLT3-mutated acute myeloid leukaemia

• Published in: British journal of haematology Vol. 204; no. 4; pp. 1227 - 1231
• Main Authors: Zucenka, Andrius, Griskevicius, Laimonas
• Format: Journal Article
• Language: English
• Published: England Blackwell Publishing Ltd 01-04-2024
• Subjects: Acute myeloid leukemia; Allografts; Aniline Compounds; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Dactinomycin; fms-Like Tyrosine Kinase 3 - genetics; Humans; Leukemia, Myeloid, Acute - drug therapy; Leukemia, Myeloid, Acute - genetics; Neoplasm Recurrence, Local; Pyrazines; Remission; Retrospective Studies; Stem cell transplantation; Sulfonamides; AML; gilteritinib; allogeneic stem cell transplantation; acute leukaemia; venetoclax; FLT3
• ISSN: 0007-1048; 1365-2141
• DOI: 10.1111/bjh.19318

We have conducted a retrospective, single-centre analysis of 20 patients with relapsed or refractory FLT3-mutated acute myeloid leukaemia (FLT3m AML) who received a salvage quadruplet regimen consisting of gilteritinib, venetoclax, low-dose cytarabine and actinomycin D (G-ACTIVE). G-ACTIVE resulted in a 95% (19/20) overall response rate and 75% (15/20) complete remission and complete remission with an incomplete platelet recovery (CR + CRp) rate. Out of 13 transplant-eligible patients, 11 (86%) proceeded to an allogeneic stem cell transplantation. The median overall survival and relapse-free survival after G-ACTIVE were 32 and 12.9 months respectively. The Day 60 mortality rate was 15%.